

Middle East and Africa Respiratory Inhalers Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Middle East and Africa Respiratory Inhalers Market Report and Forecast 2024-2032

Middle East and Africa Respiratory Inhalers Market Size

The global respiratory inhalers market was valued at USD 33.5 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising burden of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is expected to grow at a CAGR of 4.9% during the forecast period of 2024-2032, with the values likely to attain USD 53.9 billion by 2032.

Middle East and Africa Respiratory Inhalers Market Outlook

- Recent data reveals that the prevalence of asthma is relatively high in the United Arab Emirates, affecting 10-15% of the adult population along with 20-25% of school-aged children. Similarly, in South Africa, it causes substantial loss of life.
- One of the major Middle East and Africa respiratory inhalers market trends is the rising investments in the development of eco-friendly inhaler technology. In April 2024, Mundipharma, in collaboration with Vectura announced plans to reformulate an established flutiform pressurized metered-dose inhaler (pMDI), aiming to reduce the product's carbon footprint by incorporating an environmentally friendly propellant.
- The market share is influenced by the growing preference for combination inhaler therapies which consist of multiple medications in a single inhaler device, thereby driving the demand for combination inhalers.

Middle East and Africa Respiratory Inhalers Market Analysis

Respiratory inhalers are used to administer medication directly into the lungs to treat respiratory conditions. These devices contain different types of medications such as bronchodilators (to relax the muscles in the airways), corticosteroids (to reduce inflammation), and combination therapies (containing both bronchodilators and corticosteroids). There is a growing shift towards the development of combination inhaler therapies which consists of multiple medications in a single inhaler device, driving the demand for combination inhalers (aerosol or dry powder inhalers). Further, the rising advancements in digital inhaler technologies such as smart inhalers are expected to significantly contribute to the Middle East and Africa respiratory inhalers market growth.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The market is influenced by rising burden of respiratory conditions that directly impact the demand for effective respiratory inhalers. Recent data reveals that the prevalence of asthma is relatively high in the United Arab Emirates, accounting for 10-15% of the adult population and 20-25% of school-aged children. Similarly, it is estimated that over 10-15% of adults and 20% of children in South Africa are affected by asthma along with a high number of deaths caused by the condition. This increasing prevalence of respiratory diseases, attributed to factors such as smoking, air pollution, and changing lifestyle patterns, is anticipated to fuel the Middle East and Africa respiratory inhalers market demand in the coming years.

One of the major market trends include an increasing focus on the development of eco-friendly inhaler technologies in the region. For instance, in April 2024, Mundipharma (a global healthcare company with a strong presence in the Middle East and Africa) in collaboration with contract development and manufacturing organization (CDMO) Vectura announced plans to reformulate an established flutiform pressurized metered-dose inhaler (pMDI) for asthma treatment. The remodelling aims at reducing the product's carbon footprint by incorporating an environment friendly propellant. The growing efforts toward the advancement of respiratory inhaler technology with a lower environmental impact is projected to elevate the market value.

Middle East and Africa Respiratory Inhalers Market Segmentation??

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

-□ Dry Powdered Inhalers

-□ Metered Dose Inhalers

-□ Soft Mist Inhalers

-□ Nebulizers

o□ Jet Nebulizers

o□ Ultrasonic Nebulizers

o□ Mesh Nebulizers

Market Breakup by Type

-□ Conventional Inhalers

-□ Smart Inhalers

Market Breakup by Indication

-□ Asthma

-□ COPD

Market Breakup by Distribution Channel

-□ Hospital Pharmacies

-□ Retail Pharmacies

-□ Online Pharmacies

Market Breakup by End Use

-□ Hospitals

-□ Clinics

-□ Homecare Settings

-□ Others

Market Breakup by Countries

-□ Saudi Arabia

-□ United Arab Emirates

-□ Nigeria

-□ South Africa

-□ Others

Leading Players in the Middle East and Africa Respiratory Inhalers Market

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

leading key players. The major companies in the market are as follows:

- AstraZeneca Plc
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Cipla Ltd
- GSK Plc
- Koninklijke Philips NV
- OMRON Corp
- Pari Respiratory Equipment, Inc.
- Teva Pharmaceutical Industries Ltd
- OPKO Health, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

- What is the Middle East and Africa respiratory inhalers market forecast outlook for 2024-2032?

The Middle East and Africa respiratory inhalers market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 and is likely to reach a market value of USD 53.9 billion by 2032.

- What are the major factors aiding the Middle East and Africa respiratory inhalers market demand?

The rising burden of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) is fuelling the demand for the market.

- What are the major Middle East and Africa respiratory inhalers market trends?

One of the significant trends in the market is the rising investments in the development of sustainable respiratory inhalers. In April 2024, Mundipharma, in collaboration with Vectura announced plans to reformulate an established flutiform pressurized metered-dose inhaler (pMDI) with the aim to reduce the product's carbon footprint by incorporating an environmentally friendly propellant.

- What is the market segmentation based on the product?

Based on the product, the market is segmented into dry powder inhalers, metered dosed inhalers, soft mist inhalers, and nebulizers. The nebulizer category is further bifurcated into jet nebulizers ultrasonic nebulizers, and mesh nebulizers.

- What is the market breakup by type?

By type, the market is divided into conventional inhalers and smart inhalers.

- What is the market segmentation based on the indication?

The market breakup by indication includes asthma and COPD.

- What are the major end users of respiratory inhalers?

End users of the market are hospitals, clinics, and homecare settings, among others.

- What is the market segmentation by countries?

The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.

- Who are the key players involved in the Middle East and Africa respiratory inhalers market?

The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, Pari Respiratory Equipment, Inc., Teva Pharmaceutical Industries Ltd., and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

OPKO Health, Inc.

Meta description

The Middle East and Africa respiratory inhalers market is poised for growth, driven by the expansion of the global market, which was valued at USD 33.5 billion in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Middle East and Africa Respiratory Inhalers Market Overview
 - 3.1 Middle East and Africa Respiratory Inhalers Market Historical Value (2017-2023)
 - 3.2 Middle East and Africa Respiratory Inhalers Market Forecast Value (2024-2032)
- 4 Middle East and Africa Respiratory Inhalers Market Landscape*
 - 4.1 Middle East and Africa Respiratory Inhalers: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Middle East and Africa Respiratory Inhalers: Product Landscape
 - 4.2.1 Analysis by Product
 - 4.2.2 Analysis by Type
- 5 Middle East and Africa Respiratory Inhalers Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Analysis
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Middle East and Africa Respiratory Inhalers Market Segmentation (2017-2032)
 - 6.1 Middle East and Africa Respiratory Inhalers Market (2017-2032) by Product
 - 6.1.1 Market Overview
 - 6.1.2 Dry Powder Inhalers
 - 6.1.3 Metered Dosed Inhalers
 - 6.1.4 Soft Mist Inhalers
 - 6.1.5 Nebulizers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.5.1 Jet Nebulizers
- 6.1.5.2 Ultrasonic Nebulizers
- 6.1.5.3 Mesh Nebulizers
- 6.2 Middle East and Africa Respiratory Inhalers Market (2017-2032) by Type
 - 6.2.1 Market Overview
 - 6.2.2 Conventional Inhalers
 - 6.2.3 Smart Inhalers
- 6.3 Middle East and Africa Respiratory Inhalers Market (2017-2032) by Indication
 - 6.3.1 Market Overview
 - 6.3.2 Asthma
 - 6.3.3 COPD
- 6.4 Middle East and Africa Respiratory Inhalers Market (2017-2032) by End User
 - 6.4.1 Market Overview
 - 6.4.2 Hospitals
 - 6.4.3 Clinics
 - 6.4.4 Homecare Settings
 - 6.4.5 Others
- 6.5 Middle East and Africa Respiratory Inhalers Market (2017-2032) by Countries
 - 6.5.1 Market Overview
 - 6.5.2 Saudi Arabia
 - 6.5.3 United Arab Emirates
 - 6.5.4 Nigeria
 - 6.5.5 South Africa
 - 6.5.6 Others
- 7 Saudi Arabia Respiratory Inhalers Market (2017-2032)
 - 7.1 Saudi Arabia Respiratory Inhalers Market (2017-2032) by Product
 - 7.1.1 Market Overview
 - 7.1.2 Dry Powder Inhalers
 - 7.1.3 Metered Dosed Inhalers
 - 7.1.4 Soft Mist Inhalers
 - 7.1.5 Nebulizers
 - 7.1.5.1 Jet Nebulizers
 - 7.1.5.2 Ultrasonic Nebulizers
 - 7.1.5.3 Mesh Nebulizers
 - 7.2 Saudi Arabia Respiratory Inhalers Market (2017-2032) by Type
 - 7.2.1 Market Overview
 - 7.2.2 Conventional Inhalers
 - 7.2.3 Smart Inhalers
 - 7.3 Saudi Arabia Respiratory Inhalers Market (2017-2032) by Indication
 - 7.3.1 Market Overview
 - 7.3.2 Asthma
 - 7.3.3 COPD
 - 7.4 Saudi Arabia Respiratory Inhalers Market (2017-2032) by End User
 - 7.4.1 Market Overview
 - 7.4.2 Hospitals
 - 7.4.3 Clinics
 - 7.4.4 Homecare Settings

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.5 Others
- 8 United Arab Emirates Respiratory Inhalers Market (2017-2032)
 - 8.1 United Arab Emirates Respiratory Inhalers Market (2017-2032) by Product
 - 8.1.1 Market Overview
 - 8.1.2 Dry Powder Inhalers
 - 8.1.3 Metered Dosed Inhalers
 - 8.1.4 Soft Mist Inhalers
 - 8.1.5 Nebulizers
 - 8.1.5.1 Jet Nebulizers
 - 8.1.5.2 Ultrasonic Nebulizers
 - 8.1.5.3 Mesh Nebulizers
 - 8.2 United Arab Emirates Respiratory Inhalers Market (2017-2032) by Type
 - 8.2.1 Market Overview
 - 8.2.2 Conventional Inhalers
 - 8.2.3 Smart Inhalers
 - 8.3 United Arab Emirates Respiratory Inhalers Market (2017-2032) by Indication
 - 8.3.1 Market Overview
 - 8.3.2 Asthma
 - 8.3.3 COPD
 - 8.4 United Arab Emirates Respiratory Inhalers Market (2017-2032) by End User
 - 8.4.1 Market Overview
 - 8.4.2 Hospitals
 - 8.4.3 Clinics
 - 8.4.4 Homecare Settings
 - 8.4.5 Others
- 9 Nigeria Respiratory Inhalers Market (2017-2032)
 - 9.1 Nigeria Respiratory Inhalers Market (2017-2032) by Product
 - 9.1.1 Market Overview
 - 9.1.2 Dry Powder Inhalers
 - 9.1.3 Metered Dosed Inhalers
 - 9.1.4 Soft Mist Inhalers
 - 9.1.5 Nebulizers
 - 9.1.5.1 Jet Nebulizers
 - 9.1.5.2 Ultrasonic Nebulizers
 - 9.1.5.3 Mesh Nebulizers
 - 9.2 Nigeria Respiratory Inhalers Market (2017-2032) by Type
 - 9.2.1 Market Overview
 - 9.2.2 Conventional Inhalers
 - 9.2.3 Smart Inhalers
 - 9.3 Nigeria Respiratory Inhalers Market (2017-2032) by Indication
 - 9.3.1 Market Overview
 - 9.3.2 Asthma
 - 9.3.3 COPD
 - 9.4 Nigeria Respiratory Inhalers Market (2017-2032) by End User
 - 9.4.1 Market Overview
 - 9.4.2 Hospitals
 - 9.4.3 Clinics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.4 Homecare Settings
- 9.4.5 Others
- 10 South Africa Respiratory Inhalers Market (2017-2032)
 - 10.1 South Africa Respiratory Inhalers Market (2017-2032) by Product
 - 10.1.1 Market Overview
 - 10.1.2 Dry Powder Inhalers
 - 10.1.3 Metered Dosed Inhalers
 - 10.1.4 Soft Mist Inhalers
 - 10.1.5 Nebulizers
 - 10.1.5.1 Jet Nebulizers
 - 10.1.5.2 Ultrasonic Nebulizers
 - 10.1.5.3 Mesh Nebulizers
 - 10.2 South Africa Respiratory Inhalers Market (2017-2032) by Type
 - 10.2.1 Market Overview
 - 10.2.2 Conventional Inhalers
 - 10.2.3 Smart Inhalers
 - 10.3 South Africa Respiratory Inhalers Market (2017-2032) by Indication
 - 10.3.1 Market Overview
 - 10.3.2 Asthma
 - 10.3.3 COPD
 - 10.4 South Africa Respiratory Inhalers Market (2017-2032) by End User
 - 10.4.1 Market Overview
 - 10.4.2 Hospitals
 - 10.4.3 Clinics
 - 10.4.4 Homecare Settings
 - 10.4.5 Others
- 11 Regulatory Framework
- 12 Funding and Investment Analysis
 - 12.1 Analysis by Funding Instances
 - 12.2 Analysis by Type of Funding
 - 12.3 Analysis by Funding Amount
 - 12.4 Analysis by Leading Players
 - 12.5 Analysis by Leading Investors
 - 12.6 Analysis by Geography
- 13 Partnership and Collaborations Analysis
 - 13.1 Analysis by Partnership Instances
 - 13.2 Analysis by Type of Partnership
 - 13.3 Analysis by Leading Players
 - 13.4 Analysis by Geography
- 14 Supplier Landscape
 - 14.1 Market Share by Top 5 Companies
 - 14.2 AstraZeneca Plc
 - 14.2.1 Financial Analysis
 - 14.2.2 Product Portfolio
 - 14.2.3 Demographic Reach and Achievements
 - 14.2.4 Mergers and Acquisitions
 - 14.2.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.3 Beximco Pharmaceuticals Ltd.
 - 14.3.1 Financial Analysis
 - 14.3.2 Product Portfolio
 - 14.3.3 Demographic Reach and Achievements
 - 14.3.4 Mergers and Acquisitions
 - 14.3.5 Certifications
- 14.4 Boehringer Ingelheim International GmbH
 - 14.4.1 Financial Analysis
 - 14.4.2 Product Portfolio
 - 14.4.3 Demographic Reach and Achievements
 - 14.4.4 Mergers and Acquisitions
 - 14.4.5 Certifications
- 14.5 Cipla Ltd
 - 14.5.1 Financial Analysis
 - 14.5.2 Product Portfolio
 - 14.5.3 Demographic Reach and Achievements
 - 14.5.4 Mergers and Acquisitions
 - 14.5.5 Certifications
- 14.6 GSK Plc
 - 14.6.1 Financial Analysis
 - 14.6.2 Product Portfolio
 - 14.6.3 Demographic Reach and Achievements
 - 14.6.4 Mergers and Acquisitions
 - 14.6.5 Certifications
- 14.7 Koninklijke Philips NV
 - 14.7.1 Financial Analysis
 - 14.7.2 Product Portfolio
 - 14.7.3 Demographic Reach and Achievements
 - 14.7.4 Mergers and Acquisitions
 - 14.7.5 Certifications
- 14.8 OMRON Corp
 - 14.8.1 Financial Analysis
 - 14.8.2 Product Portfolio
 - 14.8.3 Demographic Reach and Achievements
 - 14.8.4 Mergers and Acquisitions
 - 14.8.5 Certification
- 14.9 Pari Respiratory Equipment, Inc.
 - 14.9.1 Financial Analysis
 - 14.9.2 Product Portfolio
 - 14.9.3 Demographic Reach and Achievements
 - 14.9.4 Mergers and Acquisitions
 - 14.9.5 Certifications
- 14.10 Teva Pharmaceutical Industries Ltd
 - 14.10.1 Financial Analysis
 - 14.10.2 Product Portfolio
 - 14.10.3 Demographic Reach and Achievements
 - 14.10.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.10.5 Certifications
- 14.11 OPKO Health, NC
 - 14.11.1 Financial Analysis
 - 14.11.2 Product Portfolio
 - 14.11.3 Demographic Reach and Achievements
 - 14.11.4 Mergers and Acquisitions
 - 14.11.5 Certifications
- 15 Middle East and Africa Respiratory Inhalers Market - Distribution Model (Additional Insight)
 - 15.1 Overview
 - 15.2 Potential Distributors
 - 15.3 Key Parameters for Distribution Partner Assessment
- 16 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 17 Company Competitiveness Analysis (Additional Insight)
 - 17.1 Very Small Companies
 - 17.2 Small Companies
 - 17.3 Mid-Sized Companies
 - 17.4 Large Companies
 - 17.5 Very Large Companies
- 18 Payment Methods (Additional Insight)
 - 18.1 Government Funded
 - 18.2 Private Insurance
 - 18.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Middle East and Africa Respiratory Inhalers Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3999.00
	Five User License	\$5299.00
	Corporate License	\$6299.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com